High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma

British Journal of Cancer

Volumn 98, Issue 8, 2008, Pages 1467-1474

  Cairney, C J ^a   Hoare, S F ^a   Daidone, M G ^b   Zaffaroni, N ^b   Keith, W N ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

ALT; Chromatin; hTERT; hTR; Liposarcoma; Telomerase

Indexed keywords

HISTONE H3; RNA; TELOMERASE;

ARTICLE; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; LIPOSARCOMA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TELOMERE;

ADULT; AGED; AGED, 80 AND OVER; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; FEMALE; HISTONES; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS (GENETICS); RNA; TELOMERASE; TELOMERE;

EID: 42149110183     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604328     Document Type: Article

References (26)

1. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN (2006) Hypoxic regulation of telomerase gene expression by transcriptional and posttranscriptional mechanisms. Oncogene 25: 61-69
2. Atkinson SP, Hoare SF, Glasspool RM, Keith WN (2005) Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 65: 7585-7590
3. Bilsland AE, Stevenson K, Atkinson S, Kolch W, Keith WN (2006) Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3. Cancer Res 66: 1363-1370
4. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3: 1271-1274
5. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14: 4240-4248
6. Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66: 407-425
7. Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR, Zaffaroni N (2006) Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 66: 8918-8924
8. Fasching CL, Bower K, Reddel RR (2005) Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res 65: 2722-2729
9. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, Royds JA (2003) Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361: 836-838
10. Henson JD, Neumann AA, Yeager TR, Reddel RR (2002) Alternative lengthening of telomeres in mammalian cells. Oncogene 21: 598-610
11. Hoare SF, Bryce LA, Wisman GB, Burns S, Going JJ, van der Zee AG, Keith WN (2001) Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer Res 61: 27-32
12. Jiang WQ, Zhong ZH, Henson JD, Reddel RR (2007) Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 26: 4635-4647
13. Johnson JE, Varkonyi RJ, Schwalm J, Cragle R, Klein-Szanto A, Patchefsky A, Cukierman E, von Mehren M, Broccoli D (2005) Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res 11: 5347-5355
14. Keith WN, Hoare SF (2004) Detection of telomerase hTERT gene expression and its splice variants by RT-PCR. Methods Mol Med 97: 297-309
15. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015
16. Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK (2004) Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 164: 1523-1529
17. Sandberg AA (2004) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 155: 1-24
18. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS (2004) Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 22: 3790-3797
19. Serakinci N, Hoare SF, Kassem M, Atkinson SP, Keith WN (2006) Telomerase promoter reprogramming and interactio with general transcription factors in the human mesenchymal stem cell. Regenerative Med 1: 125-131
20. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH, Ladanyi M (2004) Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41: 155-162
21. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M (2003) Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63: 1759-1763
22. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59: 4175-4179
23. Yi X, Shay JW, Wright WE (2001) Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 29: 4818-4825
24. Zhao J, Bilsland A, Hoare SF, Keith WN (2003) Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene. FEBS Lett 536: 111-119
25. Zhao J, Bilsland A, Jackson K, Keith WN (2005) MDM2 negatively regulates the human telomerase RNA gene promoter. BMC Cancer 5: 6
26. Zhao JQ, Glasspool RM, Hoare SF, Bilsland A, Szatmari I, Keith WN (2000) Activation of telomerase RNA gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. Neoplasia 2: 531-539